Premium
The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
Author(s) -
Ghalandari N.,
Dolhain R.J.E.M.,
Hazes J.M.W.,
Siezen C.L.E.,
Laan J.W.,
Crijns H.J.M.J.,
Puijenbroek E.P.,
Woude C.J.
Publication year - 2020
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14145
Subject(s) - medicine , infliximab , pregnancy , certolizumab pegol , breastfeeding , authorization , adalimumab , family medicine , disease , pediatrics , genetics , computer security , computer science , biology
Aims The effects of biologics on reproduction/lactation are mostly unknown although many patients that receive biologics are women of reproductive age. The first objective of this study was to investigate the publicly available data on pregnancy/lactation before and after marketing authorization in Europe of biologics for the indications of rheumatologic inflammatory autoimmune diseases and inflammatory bowel disease. Secondary objectives included the assessment of the clinical relevance of the provided data and comparison of initial and post‐authorization data. Methods Initial and post‐authorization data were extracted from the European Public Assessment Reports and the latest versions of Summary of Product Characteristics using publicly available documents on the European Medicines Agency's website. Four sections were categorized regarding pregnancy outcomes: pre‐clinical/animal studies, human female fertility, pregnancy‐related outcomes and congenital malformations in the human fetus. Three sections were categorized regarding lactation outcomes: pre‐clinical/animal studies, excretion in human breast milk and absorption in children through breastfeeding. The clinical applicability of each category was scored by specified criteria, based on scientific literature, and further as defined by the authors. Results For the 16 included biologics, post‐authorization data were delivered only for adalimumab, certolizumab pegol, etanercept and infliximab. For the 12 remaining biologics limited data on pregnancy and lactation during the post‐marketing period of 2–21 years were available. Conclusions In this article several suggestions are provided for improving a multidisciplinary approach to these issues. The initiation of suitable registries by marketing authorization holders and data transparency for clinicians and academics are highly endorsed.